Please login to the form below

Creative Bioarray

Located at Long Island, New York, Creative Bioarray was founded as biomedical company focused on providing comprehensive biotechnology and pharmaceutical array services and products for high-throughput analysis. Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample.

This is a FREE listing




Below are full profiles from other companies in this area

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we help life science companies gain the capabilities to employ the power of digital across all aspects of the marketing and sales communications.

View profile

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View profile

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create an unrivalled healthcare data, education and information resource with outstanding analytics capabilities. Binley's is a healthcare data and intelligence provider, which translates the complex NHS environment into useful information that helps organisations to increase sales, save money and improve healthcare. NHiS was founded in 2007 in response to a growing need in the marketplace for quantitative and qualitative data to inform service redesign and pathway efficiencies. Wellards provides the most up-to-date and comprehensive NHS information and training on the market.

View profile

Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Learn more about how we are Shortening the distance from lab to life® at syneoshealth.com.

View profile

Company Details

Creative Bioarray

Telephone:+1 631 624 4882

Contact

Address:
45-16 Ramsey Road Shirley
New York
NY 11967
United States

Latest content from PMHub

Live Webinar: Patient Centric Approaches for Rare and Ultra-Rare Diseases
A Fireside Chat with Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi Impetus Digital
Overcoming Patient Recruitment Challenges in Rare Disease Trials
Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments.We know patient recruitment can be challenging even for non-complex trials, but this issue is exacerbated for rare disease studies due to the much smaller patient populations involved. This can lead to lengthy delays in bringing what can be cutting-edge and potentially life-changing therapies to market.With the global rare disease market expected to be worth more than US$547 billion within the next 10 years overcoming these challenges is critical. This webinar will:explore some of the patient recruitment challenges in rare disease studies, particularly relating to sickle cell trialshear from a patient and family member about what it means to live with a rare disease and highlight strategies to accelerate patient recruitment for these specialized trials.Learning ObjectivePatient recruitment challenges in rare disease studiesChallenges in sickle cells studiesFamily/Patient perspectiveAccelerating patient recruitment in rare disease studiesSpeaker 1 - Whitney Taynton - Business Unit Head, Site Enrollment Optimization, Innovative TrialsSpeaker 2 - Donna Dail - Director, Patient Recruitment Programs (Rare Disease)Speaker 3 - Margaret Alege - Patient Innovative Trials
Medscape presents Digital Health in Practice: Impact & Insights at Reuters #Pharma2020
Medscape Education Global
Modern Medical Affairs: How to Leverage Tech and Data as an MSL
Dr. Luca Dezzani, VP of US Oncology Medical Affairs at Johnson & Johnson, explores innovation in Medical Affairs, new technologies for data dissemination and medical education, how to engage with different healthcare stakeholders, plus much more. Impetus Digital